The neurodegenerative disease therapy developer has set a $100m placeholder target for an offering following $140m in funding from investors including Amgen and Pivotal BioVentures.

US-based neurodegenerative disease drug developer Vigil Neuroscience has filed for an initial public offering on the Nasdaq Global Market, marking a potential exit for pharmaceutical firm Amgen. Founded in 2020, Vigil Neuroscience uses microglia, the main active immune cells in the central nervous system, as the basis for drugs intended to target and treat neurodegenerative…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.